Halvdelen af patienterne i hver gruppe var allerede i behandling med intravenøs epoprostenol og epoprostenoldosis var uændret i hele undersøgelsens forløb.
Half of the patients in each group were already being treated with intravenous epoprostenol and the dose of epoprostenol remained constant for the duration of the trial.